Presence of CSE1L protein in urine of patients with urinary bladder urothelial carcinomas-Reference-Cited by-同舟云学术

Presence of CSE1L protein in urine of patients with urinary bladder urothelial carcinomas

Published:2012-07 Issue:3 Volume:27 Page:280-284
ISSN:1724-6008
Container-title:The International Journal of Biological Markers
language:en
Short-container-title:Int J Biol Markers

Author:

Tai Cheng-Jeng¹²,Liao Ching-Fong³,Su Tzu-Cheng⁴,Shen Ko-Hung⁴,Chang Chun-Chao²⁵,Lin Shu-Hui⁴⁶,Yeh Chung-Min⁴⁶,Shen Shing-Chuan⁷,Lee Woan-Ruoh⁷,Chiou Jeng-Fong⁸,Lin Chih-Hung³,Chen Ying-Chun³,Shih Hsin-Yi³,Yeh Kun-Tu⁴⁹¹⁰,Jiang Ming-Chung¹

Affiliation:

1. Division of Hematology and Oncology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei - Taiwan

2. Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei - Taiwan

3. Institute of Cellular and Organismic Biology, Academia Sinica, Taipei - Taiwan

4. Department of Pathology, Changhua Christian Hospital, Changhua - Taiwan

5. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei - Taiwan

6. Jen-Teh Junior College of Medicine, Nursing and Management, Miaoli - Taiwan

7. Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei - Taiwan

8. Department of Radiation Oncology, School of Medicine, College of Medicine, Taipei Medical University, Taipei - Taiwan

9. School of Medicine, Chung Shan Medical University, Taichung - Taiwan

10. Institute of Clinical Medicine, Kaohsiung Medical University, Kaohsiung - Taiwan

Abstract

The chromosome segregation 1-like (CSE1L) protein is highly expressed in most cancers and has been shown to be secreted by tumor cells. We studied the presence of CSE1L in the urine of patients with bladder urothelial carcinomas. The results of our immunohistochemical analysis showed a high expression of CSE1L in bladder cancer specimens, while the normal bladder specimens only showed a very faint staining in some cells. Immunoblotting showed that CSE1L was present in urine of patients with bladder cancer. Urinary CSE1L-positive cases were detected in 95% (57/60) of patients with bladder urothelial carcinomas or the atypical/suspicious cases with urothelial atypia. No CSE1L was detected in urine of healthy controls (p<0.01). Our results suggest that urinary CSE1L deserves further evaluation for the screening of bladder cancer.

Publisher

SAGE Publications

Subject

Cancer Research,Clinical Biochemistry,Oncology,Pathology and Forensic Medicine

Link

http://journals.sagepub.com/doi/pdf/10.5301/JBM.2012.9310

Reference19 articles.

1. Bladder cancer, 1996

2. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers

3. EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder

4. Bladder Tumor Markers: A Review of the Literature

5. Potential new urinary markers in the early detection of bladder cancer

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognosis Risk Model Based on Necroptosis-Related Signature for Bladder Cancer;Genes;2022-11-15

2. FLVCR1 Predicts Poor Prognosis and Promotes Malignant Phenotype in Esophageal Squamous Cell Carcinoma via Upregulating CSE1L;Frontiers in Oncology;2021-03-25

3. CAS (CSE1L) signaling pathway in tumor progression and its potential as a biomarker and target for targeted therapy;Tumor Biology;2016-09-05

4. Targeting nuclear transporters in cancer: Diagnostic, prognostic and therapeutic potential;IUBMB Life;2016-03-11

5. Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts;Journal of Translational Medicine;2015-06-13